Arrowhead Research | ARWR - Gross Profit On Sales

Stock Price
64.52
Daily Change
-0.12 -0.19%
Monthly
-1.78%
Yearly
218.77%
Q1 Forecast
67.19

Arrowhead Research reported $256.47M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Agios Pharmaceuticals USD 11.2M 448K Sep/2025
Alnylam Pharmaceuticals USD 1.05B 418.14M Sep/2025
Arrowhead Research USD 256.47M 228.7M Sep/2025
Incyte USD 1.27B 130.22M Sep/2025
Ionis Pharmaceuticals USD 155M 293M Sep/2025
Ligand Pharmaceuticals USD 155.28M 82.42M Sep/2025
Merck USD 13.42B 431M Sep/2025
Moderna USD 809M 791M Sep/2025
Novartis USD 10.82B 695M Sep/2025
Sarepta Therapeutics USD 247.9M 209.96M Sep/2025
TG Therapeutics USD 133.62M 11.41M Sep/2025
Ultragenyx Pharmaceutical USD 131.94M 11.55M Sep/2025
Vertex Pharmaceuticals USD 2.66B 104.4M Sep/2025
Xencor USD 21M 22.61M Sep/2025